JavaScript is disabled in your browser. For the best experience, please enable it. All essential information and navigation links remain available below.

Sign in

Homepage
Medications
Spikevax (previously COVID-19 Vaccine Moderna)-H/C/PSUSA/00010897/202212: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Spikevax (previously COVID-19 Vaccine Moderna)-H/C/PSUSA/00010897/202212: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Spikevax (previously COVID-19 Vaccine Moderna)-H/C/PSUSA/00010897/202212: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

1 / 1

14 views

Download

Pharmaceutical

Spikevax (previously COVID-19 Vaccine Moderna)-H/C/PSUSA/00010897/202212: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Advanced pharmaceutical formulation for targeted therapeutic intervention.

Dosage

-

Strength

-

Pack Size

-

Form

-

Source

European Medicines Agency

View Source

Related Clinical Articles

Clinical Research

Clinical Research

Clinical Research

Clinical Research

Clinical Research

Clinical Research

Clinical Research

Clinical Research

View All Alternatives

Related Medications

Generic Class

Generic Class

Generic Class

Generic Class

Generic Class

Generic Class

Generic Class

Generic Class

View All Alternatives